Keyun Ren Ph.D.

任科云博士
Dr. Keyun Ren
楷拓生物科技（苏州）有限公司首席运营官
COO, CATUG Biotechnology

任科云博士有十二年生物医药研发和产业化经验，开展了十多项生物创新药物的研究，涵盖了基因治疗药物、抗体、融合蛋白等创新药，最快的产品已经进入III期临床。他从项目立项、工艺开发、IND申报、工艺放大、临床试验、工艺验证、厂房改造和建设多维度推进项目产业化工作。他建立了国际上首创的质粒富集工艺，裸质粒转染细胞治疗患者的创新基因疗法获得国内外的认可。他主持或参与国家、省市级多个项目，组建了腺病毒介导湖北省工程技术研究中心省级科研平台、靶向抗肿瘤药物湖北省工程研究中心。同时打造了基因工程药物开发及生产平台、抗体药物新分子发现关键技术平台、重组病毒与质粒生产关键工艺技术平台、人用重组DNA制品质量评价关键平台技术体系等核心技术平台。
Dr. Keyun Ren has twelve years of experience in biomedical research and industrialization. He has conducted research on more than ten innovative biopharmaceuticals, including gene therapy drugs, antibodies, and fusion proteins, with the fastest product already entering Phase III clinical trials. Dr. Ren has advanced project industrialization from multiple dimensions, including project initiation, process development, IND submission, process scaling-up, clinical trials, process validation, and facility transformation and construction.
He has established the world's first plasmid enrichment process, and his innovative gene therapy using naked plasmid transfection to treat patients has gained recognition domestically and internationally. Dr. Ren has led or participated in numerous national, provincial, and municipal-level projects, establishing provincial research platforms such as the Adenovirus-Mediated Hubei Engineering Technology Research Center and the Targeted Antitumor Drug Hubei Engineering Research Center.
In addition, he has developed and produced gene engineering drugs, discovered key technologies for new antibody drug molecules, established critical production technologies for recombinant viruses and plasmids, and developed key platform technologies for evaluating the quality of human recombinant DNA products, including the core technology platforms for antibody drug discovery and other essential technologies.